Atipamezole is a selective alpha2-adrenergic antagonist used to reverse the effects of alpha2-agonist sedatives. Its main veterinary application is reversal of medetomidine or dexmedetomidine in dogs, with additional species-specific and extra-label uses. It also has a role in selected intoxications that produce clinically important alpha2-mediated effects.
Group
Alpha-2 adrenergic antagonist
Mechanism of Action
Atipamezole competitively blocks alpha2-adrenoceptors and removes agonist-induced inhibition of norepinephrine release. Restoration of noradrenergic signaling promotes arousal and reverses alpha2-mediated sedation, analgesia and autonomic changes. The degree of reversal depends on receptor occupancy, the agonist involved and concurrent drugs. In amitraz intoxication, antagonism addresses the alpha2 activity of amitraz and its metabolites.
Dose Rates
Dogs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Dexmedetomidine reversal | 0.2 mg/kg | IM, IV | Once | |
| Amitraz toxicosis | 0.05 mg/kg | IM | Every 4–6 h | Reassess for recurrence because amitraz may outlast the antagonist. |
| Medetomidine reversal | Reference only | IM | For 5 mg/mL atipamezole and 1 mg/mL medetomidine, the source describes equal IM volumes. Prior agonist dose determines antagonist amount; retain the concentration-specific ratio. |
Cats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Dexmedetomidine reversal | 0.2 mg/kg | IM, IV | Once | |
| Medetomidine reversal | Reference only | IM | For 5 mg/mL atipamezole and 1 mg/mL medetomidine, the source describes equal IM volumes. Prior agonist dose determines antagonist amount; retain the concentration-specific ratio. |
Rabbits
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Medetomidine reversal | 0.5 mg/kg | IM, SC | Once | |
| Medetomidine reversal | 0.25 mg/kg | IV | Once |
Mice
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.1–1 mg/kg | IM, IP, IV, SC | Once |
Rats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.1–1 mg/kg | IM, IP, IV, SC | Once |
Gerbils
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.1–1 mg/kg | IM, IP, IV, SC | Once |
Hamsters
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.1–1 mg/kg | IM, IP, IV, SC | Once |
Guinea pigs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.1–1 mg/kg | IM, IP, IV, SC | Once |
Cattle
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.02–0.1 mg/kg | IV | Once | Titrate to effect. |
Sheep
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.02–0.1 mg/kg | IV | Once | Titrate to effect. |
| Alpha-2 agonist reversal - alternative | 0.1–0.2 mg/kg | IV, IM | Once | If IV, give slowly; observe the delay after dissociative combinations. |
Goats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.02–0.1 mg/kg | IV | Once | Titrate to effect. |
| Alpha-2 agonist reversal - alternative | 0.1–0.2 mg/kg | IV, IM | Once | If IV, give slowly; observe the delay after dissociative combinations. |
Llamas
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.02–0.1 mg/kg | IV | Once | Titrate to effect. |
| Alpha-2 agonist reversal - alternative | 0.1–0.2 mg/kg | IV, IM | Once | If IV, give slowly; observe the delay after dissociative combinations. |
Alpacas
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.02–0.1 mg/kg | IV | Once | Titrate to effect. |
| Alpha-2 agonist reversal - alternative | 0.1–0.2 mg/kg | IV, IM | Once | If IV, give slowly; observe the delay after dissociative combinations. |
Birds
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Alpha-2 agonist reversal | 0.5 mg/kg | IM | Once |
Reptiles
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Medetomidine reversal | Reference only | IM | Atipamezole amount 4-5 times the medetomidine dose in the ketamine/medetomidine protocol; reversal may take up to one hour. Do not give IV. |
Indications
- Reversal of medetomidine- or dexmedetomidine-associated sedation and related effects in dogs.
- Reversal of selected alpha2-agonist effects in cats, horses or other veterinary species using a supported protocol.
- Adjunctive reversal of clinically significant alpha2-mediated effects in selected amitraz poisoning.
- Specialist treatment of selected intoxications involving other alpha2 agonists, with agent-specific evidence.
Contraindications
- Avoid IV administration in reptiles because profound hypotension can occur.
- Pregnancy, lactation and breeding safety are inadequately established.
Interactions
- Antagonises alpha-2 agonists; removal of their analgesia may expose untreated pain.
- Partial alpha-1 effects may interfere with prazosin.
Adverse effects
- Vomiting, diarrhoea, salivation, tremor and abrupt excitation or aggression.
Toxicity
Overdose usually causes transient excitement, panting, vomiting or tremor. Monitor cardiovascular status.
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Antisedan 5 mg/mL Strength expressed as atipamezole hydrochloride. Source IV protocols are extralabel and do not change the labelled product route. | Injection | 5 mg / mL | IM |
Monitoring and Administration
Provide alternative analgesia before reversing a painful patient. Protect recovering animals from falls and observe for resedation.
After ketamine/tiletamine combinations in small ruminants or camelids, do not reverse too early: allow at least 30, preferably 60, minutes for the dissociative component to diminish.
The equal-volume rule applies only to the specified agonist and antagonist concentrations; it is not a universal volume rule.